Disturbed Expression of Type 1 and Type 2 Iodothyronine Deiodinase As Well As Titf1/Nkx2-1 and Pax-8 Transcription Factor Genes in Papillary Thyroid Cancer

Ambroziak, Michał; Pachucki, Janusz; Stachlewska-Nasfeter, Elżbieta; Nauman, J; Nauman, A

doi:10.1089/thy.2005.15.1137

Cited by 33 publications

(23 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One theory which explains the relationship between high fT4 and low fT3 is that as malignancy develops in the thyroid, there is a disturbed expression of type 1 iodothyronine deiodinase [26]. This would lower the rate of conversion from the inactive fT4 state to the active fT3 state and explain the relationship found in this study.…”

Section: Discussionmentioning

confidence: 50%

The T4/T3 quotient as a risk factor for differentiated thyroid cancer: A case control study

Sasson

Kay‐Rivest

Shoukrun

et al. 2017

Journal of Otolaryngology - Head & Neck Surgery

View full text Add to dashboard Cite

BackgroundThe incidence of thyroid nodules is increasing among patients in North America. Few of these nodules harbour malignancy, thus further research is required to identify predictive markers of malignant thyroid disease. This study set out to understand the relationship between the levels of fT4 and fT3 and differentiated thyroid cancer.MethodsA case-control study was conducted with 142 cases and 86 controls from the McGill University Teaching Hospitals. All patients underwent thyroid surgery. Cases were defined as patients with malignant nodules confirmed on final pathology and controls were defined as patients with benign nodules. The serological levels of TSH, fT4 and fT3 were measured preoperatively. Odds ratios were determined for each parameter and logistic regressions were calculated between markers and probability of malignancy. Additionally, fT4 values were divided by fT3 values (fT4/fT3 quotient) for each patient and an odds ratio was calculated.ResultsAmongst cases, the mean TSH was 2.25 ± 0.360U/mL, fT4 was 14.8 ± 0.689pmol/L, and fT3 was 4.65 ± 0.463pmol/L. Amongst controls, the mean TSH was 2.36 ± 1.68U/mL, fT4 was 14.3 ± 1.71pmol/L, and fT3 was 5.27 ± 0.957pmol/L. Patients in the control group were more likely to have low TSH, while patients in the case group would have high fT4 and patients in the control group were more likely to have a low fT4. The OR for patients with TSH >4.4U/mL was 2.13 (0.97, 4.65), and for patients with TSH <0.4U/mL was 0.46 (0.22, 0.95). The OR for patients with fT4 > 16pmol/L was 2.10 (1.09, 4.06), and for patients with fT4 < 10pmol/L was 0.45 (0.20, 0.98). The OR for patients with fT3 > 5.5pmol/L was 0.39 (0.14, 1.28). The OR for patients with fT3 < 3pmol/L was 1.83 (0.25, 13.69). The average fT4/fT3 was 3.39 ± 0.206 for cases and 2.93 ± 0.467 for controls. The fT4/fT3 quotient was considered high if it was >3.3 (OR =6.00 (2.94, 12.25)).ConclusionIn this study, a direct relationship between high levels of fT4 and malignancy was uncovered. Furthermore, low levels of TSH and fT4 increased the likelihood that a nodule was benign. In this study a fT4/fT3 ratio >3.3 increased the risk of malignancy by 3.6 times (p-value =0.0013).

show abstract

Section: Discussionmentioning

confidence: 50%

The T4/T3 quotient as a risk factor for differentiated thyroid cancer: A case control study

Sasson

Kay‐Rivest

Shoukrun

et al. 2017

Journal of Otolaryngology - Head & Neck Surgery

View full text Add to dashboard Cite

show abstract

“…Previous studies have reported low D1 activities in different malignant tumors, including papillary thyroid cancer [3], lung cancer [9], and renal clear cell cancer [8], as well as in benign tumors such as pituitary adenoma [10, 11]. Decreased D1 activity has also been found in papillary and follicular thyroid cancer cell lines as well as in liver hemangioma compared to healthy parenchyma [5–11].…”

Section: Discussionmentioning

confidence: 99%

“…The enzymatic activity and gene expression of D1 have been investigated in different cancer tissues. A significant decrease in both the gene expression and enzyme activity of D1 was detected in papillary thyroid cancer tissue [3, 4] as well as in papillary and follicular thyroid cancer cell lines [5, 6]. Reduced D1 enzymatic activity and/or mRNA expression has also been described in liver hemangioma [7], renal clear cell cancer [8], lung cancer [9] and pituitary adenomas [10, 11].…”

Section: Introductionmentioning

confidence: 99%

Enzymatic activity of type 1 iodothyronine deiodinase in selected liver tumors

Kornasiewicz¹,

Debski²,

Grąt³

et al. 2014

aoms

View full text Add to dashboard Cite

IntroductionType 1 iodothyronine deiodinase (D1) converts thyroxin (T4) into tri-iodothyronine (T3). Strong evidence indicates that thyroid hormone metabolism is disturbed in neoplasms such as thyroid and breast cancer. However, there is limited data concerning the function of the D1 enzyme in liver tumors. We aimed to estimate the enzymatic activity of D1 in two different common liver tumors.Material and methodsWe obtained 20 tumor samples from patients who had undergone a liver resection. Of the tissue samples, there were 13 benign lesions of focal nodular hyperplasia (FNH) and 7 malignant lesions of hepatocellular carcinomas (HCC). The D1 activity was assessed by measuring the amount of radioactive iodine released in reaction to D1-catalysed deiodination. Groups were compared by the Mann-Whitney non-parametrical test for independent trials, and the Kruskal Wallis test.ResultsThe enzymatic activity of D1 was not significantly altered in the FNH group (median = 536 fmol/mg of protein/min; p = 0.972) and HCC group (367 fmol/mg; p = 0.128) when compared to matched normal liver parenchyma controls (546 fmol/mg and 556 fmol/mg, respectively).ConclusionsLiver parenchyma expresses high levels of D1. The results clearly revealed that D1 activity was not significantly different between benign and malignant tumors (FNH and HCC) compared to healthy liver parenchyma cells.

show abstract

“…However, these enzymes are most likely also to contribute to the phenotype, because the loss of SBP2 appeared to cause a global selenoprotein synthesis defect (95). Altered expression and activity levels of DIOs have been reported in a number of tumors and cancer cell lines (7,87,170,171,324), suggesting a potential involvement of DIOs in cancer development, in particular in the thyroid.…”

Section: From Selenium To Selenoproteins 791mentioning

confidence: 99%

Untitled

2007

Antioxidants & Redox Signaling

View full text Add to dashboard Cite

Disturbed Expression of Type 1 and Type 2 Iodothyronine Deiodinase As Well As Titf1/Nkx2-1 and Pax-8 Transcription Factor Genes in Papillary Thyroid Cancer

Cited by 33 publications

References 38 publications

The T4/T3 quotient as a risk factor for differentiated thyroid cancer: A case control study

The T4/T3 quotient as a risk factor for differentiated thyroid cancer: A case control study

Enzymatic activity of type 1 iodothyronine deiodinase in selected liver tumors

Untitled

Contact Info

Product

Resources

About